3 ms·
Folic acid supplementation reduces the toxicity of a chemotherapy drug called pemetrexed, used in lung cancer and mesothelioma. That could be why it was recomme
by Gatsky 4y ago
Folic acid supplementation reduces the toxicity of a chemotherapy drug called pemetrexed, used in lung cancer and mesothelioma. That could be why it was recommended.
Sorry about your father.
- FollowingTheDao 4y agoThanks for the note about my father. But I want to show you how ridiculous it is for them to say that folic acid reduces the toxicity of PEMETREXED. The side effect of the drug is because it inhibits the folate cycle, which is why it stops cancer. So they want to give folate to someone who’s taking an anti-folate medication? Every oncologist I ask about this cannot give me a straight answer. The drug inhibit DHFR. When you take full late, you need the HFR to metabolize the folate. It’s just ridiculous and doctors have no understanding of basic nutritional biology. They were never taught in schools and they don’t care about it. Pemetrexed is chemically similar to folic acid and is in the class of chemotherapy drugs called folate antimetabolites. It works by inhibiting three enzymes used in purine and pyrimidine synthesis—thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase[16][17] (GARFT). By inhibiting the formation of precursor purine and pyrimidine nucleotides, pemetrexed prevents the formation of DNA and RNA, which are required for the growth and survival of both normal cells and cancer cells.
- adamredwoods 4y agoThe chemo cycle is designed to kill neoplasms, then to allow healthy cells recovery time. Oncologists don't want megaloblastic anemia, as that would lead to even more complications with vital organs. It looks like tests have been done, and vitamin supplements seem to be beneficial without changing efficacy: https://pubmed.ncbi.nlm.nih.gov/15117425/ https://pubmed.ncbi.nlm.nih.gov/15117425/ https://pubmed.ncbi.nlm.nih.gov/12722874/ https://pubmed.ncbi.nlm.nih.gov/12722874/